Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Consistent with clinical trial data, melflufen had an expected safety profile with manageable toxicity and clinically meaningful efficacy in patients with RRMM treated in the real-world setting.
Authors
- Clifton C. Mo (ORCID: https://orcid.org/0000-0001-8190-2484)
- Sarah Patches
- Kathryn Goodrich
- Shahrier Hossain (ORCID: https://orcid.org/0009-0004-6346-3376)
- Kim Noonan
- Paul Gerard Guy Richardson (ORCID: https://orcid.org/0000-0002-7426-8865)
- Jacob P. Laubach (ORCID: https://orcid.org/0000-0001-7565-2052)
- Kathleen O’Neill
- Houry Leblebjian
- Eileen Regan
Institutions
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1111/ejh.14398
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Dana-Farber Cancer Institute